Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2018-001976-39
    Sponsor's Protocol Code Number:GORTEC-2018-02
    National Competent Authority:France - ANSM
    Clinical Trial Type:EEA CTA
    Trial Status:Trial now transitioned
    Date on which this record was first entered in the EudraCT database:2018-10-22
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedFrance - ANSM
    A.2EudraCT number2018-001976-39
    A.3Full title of the trial
    A phase II trial of radiotherapy-durvalumab without prophylactic neck irradiation in squamous cell carcinoma of the head and neck
    Essai de phase II évaluant l’association radiothérapie-durvalumab sans irradiation prophylactique cervicale dans les carcincomes épidermoïdes de la tête et du cou
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Trial evaluating the tolerance and safety of durvalumab - radiotherapy combination for treatment of cancers of the head and neck
    Essai évaluant la tolérance et la sécurité du durvalumab associé à une radiothérapie pour le traitement des cancers de la tête et du cou
    A.3.2Name or abbreviated title of the trial where available
    REWRITe
    A.4.1Sponsor's protocol code numberGORTEC-2018-02
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorGORTEC
    B.1.3.4CountryFrance
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportGORTEC
    B.4.2CountryFrance
    B.4.1Name of organisation providing supportAstraZeneca
    B.4.2CountryUnited Kingdom
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationGORTEC
    B.5.2Functional name of contact pointCécile MICHEL
    B.5.3 Address:
    B.5.3.1Street AddressCHRU de Tours- Hôpital Bretonneau, 2 Bd Tonnellé
    B.5.3.2Town/ cityTOURS cedex 9
    B.5.3.3Post code37044
    B.5.3.4CountryFrance
    B.5.4Telephone number+33(0)2 42 06 01 78
    B.5.5Fax number+33(0)2 42 06 01 76
    B.5.6E-mailcecile.michel@gortec.fr
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameMEDI4736
    D.3.2Product code MEDI4736
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNdurvalumab
    D.3.9.1CAS number 1428935-60-7
    D.3.9.2Current sponsor codeMEDI4736
    D.3.9.4EV Substance CodeSUB122750
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Untreated Squamous cell carcinoma : Oral cavity, oropharynx, hypopharynx or larynx
    Carcinome épidermoïde non traité: Cavité orale, oropharynx, hypopharynx ou larynx
    E.1.1.1Medical condition in easily understood language
    Untreated squamous cell carcinoma of the head and neck
    Carcinome épidermoïde de la tête et du cou non traité
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10060121
    E.1.2Term Squamous cell carcinoma of head and neck
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the regional (neck) nodal control of durvalumab in combination with RT restricted to the primary tumor and the immediately adjacent nodal level (i.e. without prophylactic neck irradiation) in N0 patients with SCCHN.
    Evaluer le contrôle régional (cervical) d’un traitement par durvalumab associé à une radiothérapie du site tumoral et du premier étage ganglionnaire (sans irradiation prophylactique cervicale) chez des patients atteints d’un carcinome épidermoïde N0 de la tête et du cou.
    E.2.2Secondary objectives of the trial
    To evaluate:
    • Tolerance and safety of durvalumab combined with RT, as early and late treatment-related adverse events of grade ≥ 2 according to the NCI CTCAE V5.0
    • Local control (i.e. primary tumor site)
    • Locoregional (neck) control
    • Ultimate neck control including salvage surgery and/or RT in case of nodal relapse
    • Distant metastases control
    • Overall survival
    • Objective Response Rate
    • Progression-free survival
    • Health-related quality of life
    • Immune or biological markers potentially associated with patient outcome
    Evaluer :
    • La tolérance et sécurité d'emploi du durvalumab associé à la RT (événements indésirables de grade ≥ 2 selon NCI CTCAE v5.0)
    • Le contrôle local (site de la tumeur primaire)
    • Le contrôle locorégional (cervical)
    • Le contrôle cervical final incluant la chirurgie de rattrapage et/ou la radiothérapie en cas de rechute ganglionnaire
    • Le contrôle à distance
    • La survie globale
    • Le taux de réponse objective
    • La survie sans progression
    • La qualité de vie
    • Les marqueurs potentiels immuns ou biologiques potentiellement associés à la réponse au traitement du patient

    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Age > 18 years with no upper limit
    2. Performance Status ECOG 0-2
    3. Non-eligible to existing SOC with chemo-RT or cetuximab-RT
    4. Squamous cell carcinoma, previously untreated
    5. T1-T2 N0 with measurable disease for whom the risk of nodal spread is estimated to be low (< 10-15%) or T3-T4 N0 with measurable disease for whom large field neck irradiation may not be appropriate due to age, and/or fragile condition (PS2)
    6. N0 neck based on clinical, MRI and FDG/PET-CT examinations
    7. Oral cavity, oropharynx, hypopharynx or larynx
    8. Availability of pre-treatment tumor tissue sample (for PD-L1 expression, TILs and immune landscape)
    9. Documentation of p16 disease (HPV status for oropharyngeal tumor)
    10. Recording of alcohol consumption and smoking history
    11. Adequate normal organ and marrow function as defined below:
    - Haemoglobin > 9.0 g/dL
    - Absolute neutrophil count (ANC) ≥ 1500 per mm3
    - Platelet count > 100 000 per mm3
    - Serum bilirubin < 1.5 x institutional upper limit of normal (ULN)
    - AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional ULN
    12. Measured creatinine clearance (CL) >40 mL/min (CKD-EPI method recommended) or Calculated creatinine CL>40 mL/min by the Cockcroft-Gault formula
    13. Patient willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations during the follow up period
    14. Patient able to understand French and complete the quality of life questionnaires
    15. Must have a life expectancy of at least 12 weeks
    16. Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:
    - Women <50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).
    - Women ≥50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).
    17. Patient capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Written informed consent and any locally required authorization (eg, European Union [EU] Data Privacy Directive in the EU) obtained from the patient/legal representative prior to performing any protocol-related procedures, including screening evaluations.
    1. Age > 18 ans
    2. Performance Status ECOG 0-2
    3. Non-eligible au standard de traitement existant chimiothérapie-RT ou cetuximab-RT
    4. Carcinome épidermoïde, préalablement non traité
    5. T1-T2 N0 avec lésion mesurable avec un risque d’envahissement ganglionnaire estimé faible (< 10-15%) ou T3-T4 N0 avec lésion mesurable pour lequel une irradiation cervicale grand champ ne serait pas appropriée du fait de l’âge, et/ou d’une condition fragile (PS2)
    6. Statut cervical N0 clinique ou par IRM et FDG/PET scanner
    7. Cavité orale, oropharynx, hypopharynx ou larynx
    8. Disponibilité de tissu tumoral pré-traitement (pour recherche de l’expression PD-L1, TILs et environnement immunitaire)
    9. Pour les tumeurs de l’oropharynx, statut p16 connu (HPV)
    10. Documentation de la consommation d’alcool et de tabac
    11. Fonction hématologique et hépatique adéquate :
    - Hémoglobine > 9.0 g/dL
    - Polynucléaires neutrophiles (PNN) ≥ 1500 par mm3
    - Plaquettes ≥ 100 000 par mm3
    - Bilirubine totale < 1.5 x limite supérieure de la normale
    - AST (SGOT)/ALT (SGPT) ≤ 2.5 x limite supérieure de la normale
    12. Clairance à la creatinine mesurée (CL) >40 mL/min (méthode CKD-EPI recommandée) ou calculée par la méthode de Cockcroft-Gault
    13. Patient acceptant de se conformer au traitement et visites de l’étude durant les phases de traitement et de suivi
    14. Patient capable de comprendre le français et de compléter les questionnaires de qualité de vie
    15. Espérance de vie estimée à plus de 12 semaines
    16. Patiente post-ménopausée ou femme non ménopausée ayant un test de grossesse urinaire ou sanguin négatif. Une femme sera considérée post ménopausée en cas d’aménorrhées depuis au moins 12 mois sans autre cause médicale. Les exigences spécifiques à l’âge suivantes s’appliqueront :
    - Femme <50 ans sera considérée post-ménopausée si elle est aménorrhique depuis au moins 12 mois après l’arrêt de traitement hormonal exogène et si elle a des dosages de LH et FSH en adéquation avec un statut ménopausique ou qu’elle a subi une chirurgie stérilisante (oophorectomie bilatérale ou hystérectomie)
    - Femme ≥50 ans sera considérée post-ménopausée si elle est aménorrhique depuis au moins 12 mois après l’arrêt de traitement hormonal exogène, a une ménopause radio ou chimio-induite avec les dernières règles >1 an, ou qu’elle a subi une chirurgie stérilisante (oophorectomie bilatérale ou hystérectomie)
    17. Consentement éclairé signé obtenu avant toute procédure à l’étude

    E.4Principal exclusion criteria
    1. Nasopharyngeal, paranasal sinuses, nasal cavity tumors or thyroid cancers
    2. Metastatic disease
    3. Active CNS disease
    4. Any prior or current treatment for invasive head and neck cancer
    5. Any unresolved toxicity NCI CTCAE V5.0 Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria.
    a. Patients with Grade ≥2 neuropathy will be evaluated on a case-by-case basis
    b. Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after consultation with the investigator
    6. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP. Note: Local surgery of isolated lesions for palliative intent is acceptable
    7. History of leptomeningeal carcinomatosis
    8. Body weight ≤ 30 kg and/or weight loss of ≥ 15% during the last 4 weeks (except if re-nutrition with a feeding tube is planned before the onset of treatment or is ongoing)
    9. Concurrent treatment with any other systemic anti-cancer therapy that is not specified in the protocol
    10. Concomitant treatment with any drug on the prohibited medication list such as live vaccines within 30 days prior to the first dose of IP
    11. Known allergy or hypersensitivity reaction to study drug or any of the study drug excipients
    12. Prior organ transplantation including allogenic stem-cell transplantation
    13. Other severe acute or chronic medical conditions including pneumonitis, pulmonary fibrosis
    14. Active autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc])
    15. Uncontrolled intercurrent illness, including but not limited to, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent
    16. History of another primary malignancy except for:
    a. Malignancy treated with curative intent and with no known active disease ≥ 5 years
    b. Adequately treated non-melanoma skin cancer
    c. Adequately treated carcinoma in situ without evidence of disease
    17. History of active primary immunodeficiency
    18. Ongoing or active infection including tuberculosis, hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA
    19. Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion:
    a. Intranasal, inhaled, topical steroids, or local steroid injections
    b. Systemic corticosteroids < 10 mg/day of prednisone or its equivalent
    c. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)
    20. Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy
    21. Prior randomization or treatment in a previous durvalumab clinical study regardless of treatment arm assignment
    1. Tumeurs du nasopharynx, des sinus, de la cavité nasale ou de la thyroïde
    2. Maladie métastatique
    3. Maladie active du système nerveux central
    4. Traitement antérieur ou en cours pour un cancer ORL invasif
    5. Toxicités non résolues de grade ≥2 (NCI CTCAE) d’un traitement oncologique precedent à l’exception de l’alopécie, du vitiligo, et de valeurs de laboratoire définies dans les critères d’inclusion.
    a. Les patients avec une neuropathie de Grade ≥2 seront évalués au cas par cas
    b. Les patients présentant une toxicité irreversible qui ne devrait pas raisonnablement être aggravée par le traitement par durvalumab pourront être inclus après une
    consultation avec l’investigateur
    6. Procédure chirurgicale majeure selon l’investigateur dans les 28 jours avant la première administration du traitement à l’étude. NB: une chirurgie locale est acceptable
    7. Antécédent de carcinomatose leptoméningée
    8. Poids ≤ 30 kg et/ou perte de poids ≥ 15% durant les 4 dernières semaines (sauf si nutrition par sonde/gastrostomie en cours ou prévue avant le début de traitement)
    9. Traitement concomitant avec tout autre traitement anticancéreux systémique non spécifié dans le protocole
    10. Traitement concomitant avec un traitement interdit mentionné dans le protocole tel que les vaccins vivants
    11. Réaction connue d’hypersensibilité au traitement à l’étude ou à un de ses excipients
    12. Antécédent de transplantation d’organe, y compris greffe de cellules souches allogéniques
    13. Autre affection sévère aigüe ou chronique, y compris inflammation pulmonaire, fibrose pulmonaire
    14. Maladie autoimmune active ou désordres inflammatoires (incluant maladie inflammatoire de l’intestin [ex colite ou maladie de Crohn], lupus érythémateux systémique, syndrome de Sarcoïdose, ou syndrome de Wegener [granulomatose avec polyangéite, maladie de Graves, arthrite rhumatoïde, hypophysite, uveite, etc])
    15. Maladie intercurrente non contrôlée, incluant mais non limitée à: infection en cours ou active, insuffisance cardiaque congestive symptomatique, hypertension non contrôlée, angor instable, arrythmie cardiaque, maladie gastrointestinale sévère chronique, ou affections psychiatriques/situations sociales qui pourraient limiter l’adhésion du patient à l’étude, ou augmenter substantiellement le risque d’événement indésirable ou compromettre la capacité du patient à donner son consentement éclairé
    16. Antécédent d’autre cancer à l’exception des :
    a. Cancer traité en intention curative sans maladie active depuis au moins 5 ans
    b. Carcinomes cutanés autres que mélanomes adéquatement traités
    c. Carcinomes in situ adéquatement traités sans évidence de maladie
    17. Antécédent d’immunodéficience primaire active
    18. Infection active incluant la tuberculose, l’hépatite B (statut positif HBV par HBsAg), hépatite C, ou VIH (Anticorps HIV 1/2 positifs). Les patients avec un antécédent
    d’infection à l’hépatite ou infection résolue (définie par la présence d’anticorps à l’hépatite B [anti-HBc] et l’absence d’HBsAg) sont éligibles. Les patients positifs pour l’hépatite C (VHC) sont éligibles seulement si la chaine de réaction à la polymerase est négative pour l’ARN VHC
    19. Traitement immunosuppresseur en cours ou dans les 14 jours de la 1ère dose de durvalumab, à l’exception de :
    a. Stéroïdes intranasals, inhalés, topiques, ou injections locales de stéroïdes
    b. Corticosteroïdes systémiques < 10 mg/jour de prednisone ou équivalents
    c. Stéroïdes donnés en prémédication des réactions d’hypersensibilité (ex prémédication pour scanner)
    20. Patiente enceinte ou allaitante ou homme ou femme en âge de procréer qui ne voudrait pas utiliser une méthode contraceptive du screening à 90 jours après la dernière dose de durvalumab
    21. Randomisation ou traitement dans un essai clinique sur le durvalumab quelque soit le bras alloué
    E.5 End points
    E.5.1Primary end point(s)
    Regional (neck) nodal control rate
    Contrôle ganglionnaire régional (cervical)
    E.5.1.1Timepoint(s) of evaluation of this end point
    1 year after treatment
    1 an après le traitement
    E.5.2Secondary end point(s)
    • Early and late adverse events of grade ≥ 2, according to the CTCAE V5.0
    • Local control at the primary site
    • Locoregional nodal + primary site control rate
    • Distant metastases control rate
    • Ultimate regional control including salvage surgery and/or salvage RT)
    • Overall survival
    • Objective Response Rate
    • Progression-free survival
    • QLQ C30 and QLQ-H&N35 scores at baseline, 3, 15 and 27 months post RT
    • Evénements indésirables précoces et tardifs de grade ≥ 2, selon les CTCAE V5.0
    • Taux de contrôle local du site primitif
    • Taux de contrôle locorégional ganglionnaire + site primitif
    • Taux de contrôle regional final incluant la chirurgie et/ou RT de rattrapage
    • Taux de contrôle des métastases à distance
    • Survie globale
    • Taux de réponse objective
    • Survie sans progression
    • Scores du QLQ C30 et QLQ-H&N35 scores à Baseline, 3, 15 et 27 mois post RT
    E.5.2.1Timepoint(s) of evaluation of this end point
    During treatment
    Pendant le traitement
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned14
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA14
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Switzerland
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years
    E.8.9.1In the Member State concerned months16
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial months16
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 60
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 13
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state68
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 68
    F.4.2.2In the whole clinical trial 73
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    According to local standards at investigator choice
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2018-12-14
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2018-11-22
    P. End of Trial
    P.End of Trial StatusTrial now transitioned
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 03:02:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA